Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Protocol for a randomised trial of triple anti-Heliocobacter therapy versus chlorambucil in an endoscopically diagnosed low grade gastric lymphoma
Source of recordUK Trials
ISRCTNISRCTN43154562
Date ISRCTN assigned01/07/2001
Local reference number(s)LY03
Public titleProtocol for a randomised trial of triple anti-Heliocobacter therapy versus chlorambucil in an endoscopically diagnosed low grade gastric lymphoma
Scientific title
AcronymNot Applicable
Disease/condition/study domainLymphoma (non-Hodgkins)
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Non-resected, partially or completely resected low grade gastric lymphoma
2. Age 16 or over
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated end date18/05/2001
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsPatients are randomised to one of two treatment regimens:

1. Regimen A: Colloidal bismuth 120 mg four times daily, metronidazole, 400 mg three times daily plus tetracycline 500 mg four times daily or amoxycillin 500 mg four times daily. In addition patients receive chlorambucil daily for 14 days, cycle to be repeated every 28 days for six cycles.

2. Regimen B: Colloidal bismuth 120 mg four times daily, metronidazole, 400 mg three times daily plus tetracycline 500 mg four times daily or amoxycillin 500 mg four times daily. No chlorambucil.
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingCancer Research UK
Sponsor nameCancer Research UK
Sponsor detailsPO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
Sponsor telephone+44 (0)20 7317 5186
Sponsor fax+44 (0)20 7487 4302
Sponsor emailkate.law@cancer.org.uk
Sponsor websitehttp://www.cancer.org.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN43154562
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central